CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates

被引:40
作者
Gauduin, MC
Allaway, GP
Olson, WC
Weir, R
Maddon, PJ
Koup, RA
机构
[1] Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[2] Rockefeller Univ, New York, NY 10016 USA
[3] Progen Pharmaceut Inc, Tarrytown, NY 10591 USA
关键词
D O I
10.1128/JVI.72.4.3475-3478.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
CD4-immunoglobulin G2 (IgG2) is a fusion protein comprising human IgG2 in which the Fv portions of both heavy and light chains have been replaced by the V1 and V2 domains of human CD4. Previous studies found that CD4-IgG2 potently neutralizes a broad range of primary human immunodeficiency virus type 1 (HIV-1) isolates in vitro and ex vivo. The current report demonstrates that CD4-IgG2 protects against infection by primary isolates of HIV-1 in vivo, using the hu-PBL-SCID mouse model. Passive administration of 10 mg of CD4-Igc2 per kg of body weight protected all animals against subsequent challenge with 10 mouse infectious doses of the laboratory-adapted T-cell-tropic isolate HIV-1(LAI), while 50 mg of CD4-IgG2 per kg protected four of five mice against the primary isolates HIV-1(JR-CSF) and HIV-1(AD6). In contrast, a polyclonal HIV-1 Ig fraction exhibited partial protection against HIV-1(LAI) at 150 mg/kg but no significant protection against the primary HIV-1 isolates. The results demonstrate that CD4-IgG2 effectively neutralizes primary HIV-1 isolates in vivo and can prevent the initiation of infection by these viruses.
引用
收藏
页码:3475 / 3478
页数:4
相关论文
共 21 条
[1]   EXPRESSION AND CHARACTERIZATION OF CD4-IGG(2), A NOVEL HETEROTETRAMER THAT NEUTRALIZES PRIMARY HIV TYPE-1 ISOLATES [J].
ALLAWAY, GP ;
DAVISBRUNO, KL ;
BEAUDRY, GA ;
GARCIA, EB ;
WONG, EL ;
RYDER, AM ;
HASEL, KW ;
GAUDUIN, MC ;
KOUP, RA ;
MCDOUGAL, JS ;
MADDON, PJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (05) :533-539
[2]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871
[3]   JITTERS JEOPARDIZE AIDS VACCINE TRIALS [J].
COHEN, J .
SCIENCE, 1993, 262 (5136) :980-981
[4]   PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY GP120 V3 DOMAIN-SPECIFIC MONOCLONAL-ANTIBODY [J].
EMINI, EA ;
SCHLEIF, WA ;
NUNBERG, JH ;
CONLEY, AJ ;
EDA, Y ;
TOKIYOSHI, S ;
PUTNEY, SD ;
MATSUSHITA, S ;
COBB, KE ;
JETT, CM ;
EICHBERG, JW ;
MURTHY, KK .
NATURE, 1992, 355 (6362) :728-730
[5]   PREEXPOSURE AND POSTEXPOSURE PROTECTION AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION MEDIATED BY A MONOCLONAL-ANTIBODY [J].
GAUDUIN, MC ;
SAFRIT, JT ;
WEIR, R ;
FUNG, MSC ;
KOUP, RA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1203-1209
[6]   Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules [J].
Gauduin, MC ;
Allaway, GP ;
Maddon, PJ ;
Barbas, CF ;
Burton, DR ;
Koup, RA .
JOURNAL OF VIROLOGY, 1996, 70 (04) :2586-2592
[7]   Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 [J].
Gauduin, MC ;
Parren, PWHI ;
Weir, R ;
Barbas, CF ;
Burton, DR ;
Koup, RA .
NATURE MEDICINE, 1997, 3 (12) :1389-1393
[8]  
HARRIS WJ, 1997, ANTIBODY THERAPEUTIC, P89
[9]   QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS [J].
HO, DD ;
MOUDGIL, T ;
ALAM, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) :1621-1625
[10]   QUANTITATIVE ASSESSMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION IN HUMAN XENOGRAFTS OF ACUTELY INFECTED HU-PBL-SCID MICE [J].
KOUP, RA ;
HESSELTON, RM ;
SAFRIT, JT ;
SOMASUNDARAN, M ;
SULLIVAN, JL .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (03) :279-284